Saturday 17 October 2026
Export LUCY’s income statement to Excel — free account
Innovative Eyewear, Inc.
LUCY Healthcare Medical Instruments & Supplies
Innovative Eyewear, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 million, up 62.7% from fiscal 2024. In the quarter to June 2026, revenue grew 74.5%, EPS grew 60.6%, free cash flow grew 9.61% and total debt fell 92.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
0.79
0.05
−5.95%
Follow LUCY
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 14.00 | 7.28 | 3.26 | 0.95 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 140.00 | 110.00 | 27.20 | 7.08 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 9 | 9 | 11 | 11 | 13 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.08 | 0.07 | 0.10 | 0.15 | 0.20 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | 1 | 1 | 1 | 2 | 3 | ||||
| Gross margin, % | — | — | — | — | (30.35) | 21.47 | (8.53) | (10.35) | 13.15 | 21.32 | |||||
| EBT | — | — | — | — | (1) | (3) | (6) | (7) | (8) | (8) | |||||
| EBT margin, % | — | — | — | — | (1,347.72) | (469.74) | (861.14) | (578.17) | (474.61) | (285.20) | |||||
| Net income | — | — | — | — | (1) | (3) | (6) | (7) | (8) | (8) | |||||
| Depreciation | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.39 | 2.63 | 2.02 | 1.88 | 1.09 | 0.67 | ||||
| Earnings | — | — | — | — | (5.19) | (12.40) | (15.55) | (12.60) | (5.19) | (1.90) | |||||
| Cash flow | — | — | — | — | (0.27) | (4.63) | (9.88) | (9.41) | (4.51) | (1.82) | |||||
| Capex | — | — | — | — | (0.40) | (0.45) | (0.67) | (0.41) | (0.32) | (0.06) | |||||
| Free cash flow | — | — | — | — | (0.67) | (5.08) | (10.55) | (9.81) | (4.82) | (1.88) | |||||
| Book value | — | — | — | — | (3.75) | 0.79 | 12.33 | 9.07 | 6.08 | 2.27 | |||||
| Shares, m | — | — | — | — | 0 | 0 | 0 | 1 | 1 | 4 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | 48.32 | 48.32 | 12.37 | 4.79 | 4.50 | 1.50 | |||||
| P/B | — | — | — | — | 0.00 | 0.00 | 2.03 | 0.99 | 0.81 | 0.44 | |||||
| EV/Sales | — | — | — | — | 50.90 | 50.90 | 7.02 | 1.12 | (0.06) | (0.91) | |||||
| EV/FCF | — | — | — | — | (17.27) | (17.27) | (1.35) | (0.21) | 0.01 | 0.32 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (1) | (3) | (6) | (7) | (7) | ||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | 0 | (1) | (3) | (6) | (7) | (8) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | (1) | 0 | 4 | 5 | 9 | 8 | ||||
| Total debt | — | — | — | — | 1 | 0 | 0 | — | — | 0 | |||||
| Net debt | — | — | — | — | 1 | 0 | (4) | (4) | (8) | (6) | |||||
| Shareholders’ equity | — | — | — | — | (1) | 0 | 4 | 6 | 9 | 9 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (626.77) | (206.08) | (122.17) | (96.74) | (75.99) | ||||
| ROIC | — | — | — | — | (2,702.33) | (480.61) | (704.56) | (337.01) | (315.25) | (205.50) | |||||
| ROE | — | — | — | — | 0.00 | 1,868.41 | (268.52) | (139.06) | (106.00) | (83.60) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Innovative Eyewear, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MLSS Milestone Scientific, Inc. | $29.6M | — (loss-making) | — (loss-making) | +22.27% (above 0%: growing) | n/m | +66.68% (above 0%: growing) | 67.24% | (37.37%) | Compare |
| RVP Retractable Technologies, Inc. | $17.6M | — (loss-making) | 11.1× | −31.07% (below 0%: shrinking) | n/m | +56.67% (above 0%: growing) | 2.65% | (71.46%) | Compare |
| BNGO Bionano Genomics, Inc. | $16.1M | — (loss-making) | — (loss-making) | +21.36% (above 0%: growing) | n/m | −33.93% (below 0%: shrinking) | 52.80% | (88.34%) | Compare |
| NXGL NexGel, Inc. | $15.9M | — (loss-making) | — (loss-making) | +27.81% (above 0%: growing) | n/m | −432.32% (below 0%: shrinking) | 30.09% | (67.96%) | Compare |
| FEMY Femasys Inc. | $14.5M | — (loss-making) | — (loss-making) | −18.93% (below 0%: shrinking) | n/m | +11.29% (above 0%: growing) | 57.08% | (1,526.79%) | Compare |
| CUPR Cuprina Holdings (Cayman) Limited | $11.5M | — | — | — | — | — | — | — | Compare |
| RGNT Regentis Biomaterials Ltd. | $10.9M | — | — | — | — | −132.79% (below 0%: shrinking) | — | — | Compare |
| LUCY Innovative Eyewear, Inc. | $7.3M | — (loss-making) | — | +74.46% (above 0%: growing) | n/m | +9.61% (above 0%: growing) | 24.00% | (168.73%) | |
| MHUAF Meihua International Medical Technologies Co., Ltd. | $4.3M | — | — | — | — | −61.55% (below 0%: shrinking) | 35.48% | 0.00% | Compare |
| Median of peers | $15.2M | — | — | +21.36% | — | −33.93% | 44.14% | (69.71%) |
Innovative Eyewear, Inc. (LUCY) key facts
- Strength: Innovative Eyewear, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 million, up 62.7% from fiscal 2024.
- Innovative Eyewear, Inc. (LUCY) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, LUCY traded at $0.79, a market capitalization of $7.3 million.
- Return on equity was −83.6% and debt-to-equity 0.00.
- Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −3.75 (distress zone) for fiscal 2025.
Innovative Eyewear, Inc. (LUCY) Latest News
No news at this impact. Lower the threshold for more.